Dietary Supplement OTC Monograph Claims Opposed By CSPI
This article was originally published in The Tan Sheet
FDA should "modify language" in the structure/ function claims final rule to "prohibit dietary supplements from carrying the same claims as those that are approved for over-the-counter (OTC) drugs," the Center for Science in the Public Interest states in a March 30 citizen petition.
You may also be interested in...
Amendment of the structure/function claims final rule to prohibit statements concerning edema associated with pregnancy is requested by CHPA in a citizen petition filed with FDA May 11. The trade group asks the agency to issue a regulation requiring label statements on certain dietary supplements pertaining to their use by women who are pregnant or nursing, and calls on CFSAN to develop a guidance on the "scientific basis for assessing the potential for possible effects of dietary supplements on reproduction/development and the scope and nature of safety-related evidence that is needed to support a structure/function claim for conditions associated with pregnancy and nursing." CHPA suggests FDA use the association's voluntary pregnancy/nursing labeling program, announced in March, as a basis for creating a regulatory framework (1"The Tan Sheet" March 27, p. 3)
Some OTC drug monograph claims may be acceptable dietary supplement structure/function claims, FDA concludes in the final rule on supplement claims criteria published in the Jan. 6 Federal Register. However, others would be disease claims if used on supplement products, the agency adds.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC